Serum ferritin is a marker of morbidity and mortality in hemodialysis patients

被引:119
作者
Kalantar-Zadeh, K [1 ]
Don, BR [1 ]
Rodriguez, RA [1 ]
Humphreys, MH [1 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Nephrol, San Francisco, CA 94143 USA
关键词
dialysis; ferritin; albumin; transferrin; anemia; acute-phase reactant; mortality; hospitalization;
D O I
10.1053/ajkd.2001.22433
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We tested the hypothesis that a high concentration of serum ferritin, a frequently used marker of iron stores in dialysis patients and an acute-phase reactant, may be a marker of morbidity and mortality in these patients. To evaluate the impact of ferritin on morbidity and mortality, we reviewed the g-month hospitalization rates in our dialysis patients retrospectively and subsequently reviewed the mortality among these patients over a 12-month period of time prospectively. One hundred one adult hemodialysis patients (59 men and 42 women; age, 54 +/- 15 years) who had been on hemodialysis for 38 +/- 27 months were studied. All but 5 patients were on intravenous iron with similar iron administration pattern. In the retrospective cohort, ferritin's correlation coefficients for hospitalization days end frequency (both r = +0.39, P < 0.001) were higher compared with the albumin correlations for hospitalization days (r = -0.31, P = 0.001) and frequency (r = -0.28, P = 0.005) and correlation coefficients remained similarly significant after case-mix adjustment. In the prospective study, the "predeath" value of serum ferritin for 17 deceased patients (891 +/- 476 ng/mL) was higher than both their "initial" value (619 +/- 345 ng/mL, P = 0.007) and the mean ferritin value of 84 surviving and withdrawing patients (639 +/- 358 ng/mL, P = 0.001). Although Cox proportional hazard analysis showed a significant odds ratio of death only for serum albumin and not for ferritin, logistic regression analysis using the predeath values confirmed the significant impact of both decreased serum albumin and increased serum ferritin as markers of dialysis mortality. After case-mix adjustment, the relative risks of death for a 500 ng/dL increase in serum ferritin was 2.71 (95% confidence interval, 1.06 to 7.02) and for a 0.5 g/dL decrease in serum albumin was 4.48 (95% confidence interval, 1.77 to 11.33). Hence, serum ferritin is a strong predictor of hospitalization in dialysis patients. Although serum albumin is found to be a strong long-term marker of mortality in hemodialysis patients, an increase in serum ferritin appears to be a more reliable short-term marker of death over a 12-month period. Therefore, in the setting of uniform iron administration, a high serum ferritin may be a morbidity risk factor and a recent increase in serum ferritin may carry an increase in the risk of death in these patients. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:564 / 572
页数:9
相关论文
共 30 条
[1]   Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease Core Indicators Project [J].
Bailie, GR ;
Frankenfield, DL ;
Prowant, BF ;
McClellan, W ;
Rocco, MV .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (06) :1187-1189
[2]  
Barany P, 1997, MINER ELECTROL METAB, V23, P273
[3]  
BROWNER WS, 1998, DESIGNING CLIN RES E, P128
[4]   Iron status as measured by serum ferritin: The marker and its limitations [J].
Cavill, I .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (04) :S12-S17
[5]   Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy [J].
Eschbach, JW ;
Adamson, JW .
KIDNEY INTERNATIONAL, 1999, 55 :S35-S43
[6]   Diagnosis of iron deficiency in chronic renal failure [J].
Fernández-Rodríguez, AM ;
Guindeo-Casasús, MC ;
Molero-Labarta, T ;
Domínguez-Cabrera, C ;
Hortal-Cascón, L ;
Pérez-Borges, P ;
Vega-Díaz, N ;
Saavedra-Santana, P ;
Palop-Cubillo, L .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :508-513
[7]   Iron management in end-stage renal disease [J].
Fishbane, S ;
Maesaka, JK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (03) :319-333
[8]  
Fishbane S, 1998, Am J Kidney Dis, V32, pS152, DOI 10.1016/S0272-6386(98)70179-9
[9]   Review of issues relating to iron and infection [J].
Fishbane, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (04) :S47-S52
[10]   Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454